#ASCO21: Bristol Myers' solo, dual I/O regimens best chemo alone — with one exception — in first-line esophageal patients
Bristol Myers Squibb has made a big push in recent years to take its anti-PD(L)1 Opdivo — both solo and in combination with Yervoy — into gastrointestinal …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
